Gralla R J, Cvitkovic E, Golbey R B
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1585-8.
The role of cis-dichlorodiammineplatinum(II) (cis-platinum) as a single agent in non-small cell lung cancer has not been clearly defined, and extensive phase II studies have not been conducted. However, objective responses were noted in several early clinical trials. A review of these reports, including combinations with conventional agents, shows 15 partial responses among 100 patients. Results are presented on a new protocol using high-dose cis-platinum with mannitol-induced diuresis combined with cyclophosphamide and Adriamycin. An overall partial response rate of 28% was observed, including a 38% response rate in good performance status patients, with a median survival of 16 months in responding patients. Data from recent combination protocols do not define the activity of cis-platinum as a single agent, but suggest that it may be useful in non-small cell carcinoma of the lung.
顺式二氯二氨铂（II）（顺铂）作为单一药物在非小细胞肺癌中的作用尚未明确界定，且尚未进行广泛的II期研究。然而，在一些早期临床试验中观察到了客观缓解。对这些报告的综述，包括与传统药物联合使用的情况，显示100例患者中有15例部分缓解。本文介绍了一种新方案的结果，该方案使用高剂量顺铂联合甘露醇诱导利尿，并联合环磷酰胺和阿霉素。观察到总体部分缓解率为28%，其中身体状况良好的患者缓解率为38%，缓解患者的中位生存期为16个月。近期联合方案的数据并未明确顺铂作为单一药物的活性，但表明它可能对肺非小细胞癌有用。
